MED vs. LMNR, CSV, BYND, CBUS, SENEA, YSG, LWAY, DJCO, TPB, and CVGW
Should you be buying Medifast stock or one of its competitors? The main competitors of Medifast include Limoneira (LMNR), Carriage Services (CSV), Beyond Meat (BYND), Cibus (CBUS), Seneca Foods (SENEA), Yatsen (YSG), Lifeway Foods (LWAY), Daily Journal (DJCO), Turning Point Brands (TPB), and Calavo Growers (CVGW). These companies are all part of the "consumer staples" sector.
Medifast (NYSE:MED) and Limoneira (NASDAQ:LMNR) are both small-cap consumer staples companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends.
Medifast currently has a consensus price target of $61.00, indicating a potential upside of 80.96%. Limoneira has a consensus price target of $23.00, indicating a potential upside of 15.87%. Given Medifast's higher probable upside, analysts plainly believe Medifast is more favorable than Limoneira.
Medifast received 94 more outperform votes than Limoneira when rated by MarketBeat users. Likewise, 64.05% of users gave Medifast an outperform vote while only 62.42% of users gave Limoneira an outperform vote.
Medifast has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Limoneira has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.
Medifast pays an annual dividend of $6.60 per share and has a dividend yield of 19.6%. Limoneira pays an annual dividend of $0.30 per share and has a dividend yield of 1.5%. Medifast pays out 72.4% of its earnings in the form of a dividend. Limoneira pays out -51.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Medifast has a net margin of 9.27% compared to Limoneira's net margin of -5.40%. Medifast's return on equity of 56.06% beat Limoneira's return on equity.
In the previous week, Medifast had 1 more articles in the media than Limoneira. MarketBeat recorded 2 mentions for Medifast and 1 mentions for Limoneira. Limoneira's average media sentiment score of 0.05 beat Medifast's score of 0.00 indicating that Limoneira is being referred to more favorably in the news media.
95.5% of Medifast shares are held by institutional investors. Comparatively, 64.3% of Limoneira shares are held by institutional investors. 2.1% of Medifast shares are held by insiders. Comparatively, 9.0% of Limoneira shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Medifast has higher revenue and earnings than Limoneira. Limoneira is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.
Summary
Medifast beats Limoneira on 14 of the 20 factors compared between the two stocks.
Get Medifast News Delivered to You Automatically
Sign up to receive the latest news and ratings for MED and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medifast Competitors List
Related Companies and Tools
